Canaccord Genuity Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Neutral 57.8%

Neg 0% Neu 57.8% Pos 0%

Canaccord Genuity analyst William Plovanic initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $32.